We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mirtazapine for Sleep Disorders in Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01867775
Recruitment Status : Unknown
Verified May 2013 by Einstein Francisco de Camargos, Brasilia University Hospital.
Recruitment status was:  Recruiting
First Posted : June 4, 2013
Last Update Posted : June 4, 2013
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to determine whether mirtazapine is effective in the treatment of sleep disorders in Alzheimers disease.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Sleep Disorders Drug: Mirtazapine Phase 3

Detailed Description:

Mirtazapine has been used for depressed elderly with sleep disorders with good tolerability and efficacy. The study hypothesis is that mirtazapine could also be used in demented with sleep disorders.

Sleep disorders (SD) affects 35 to 50 percent of patients with Alzheimer Disease (AD). These disorders often make caring for patients at home very difficult and It's also associated with higher risk of institutionalization and increases health care costs. Treatment of SD in people with dementia may benefit both patients and their caregivers. However, little is known about the efficacy of pharmacological treatments for treating sleep disturbances in AD.


Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Mirtazapine for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Double-blind, Placebo-controlled Study
Study Start Date : May 2012
Estimated Primary Completion Date : December 2013
Estimated Study Completion Date : May 2014


Arms and Interventions

Arm Intervention/treatment
Active Comparator: Mirtazapine
Mirtazapine, 15 mg once a day, at night for 14 days
Drug: Mirtazapine
Mirtazapine 15 mg, at night, once a day for 14 days
Other Name: Remeron
Placebo Comparator: Placebo
Placebo 15 mg, once a day at night for 14 days


Outcome Measures

Primary Outcome Measures :
  1. Change From Baseline in Nighttime Total Sleep Time [ Time Frame: Baseline, 14 days follow-up ]
    Mean of Nighttime Total Sleep Time (in minutes) during the 12-h nocturnal epoch 8:00 PM - 08:00 AM after 2 weeks under treatment


Secondary Outcome Measures :
  1. Change From Baseline in Nighttime Number Of Awakenings [ Time Frame: Baseline, 14 days follow-up ]
    Change in scores from baseline to intervention week was analyzed using an analysis of covariance (ANCOVA) with the change score as the dependent variable and the treatment condition and baseline score as independent variables.

  2. Change From Baseline in Nighttime Wake After Sleep Onset [ Time Frame: Baseline, 14 days follow-up ]
    Nighttime Wake After Sleep Onset (in minutes) after sleep onset until the final awakening during the 12-h nocturnal epoch 8:00 PM - 08:00 AM. After 2 weeks under treatment.

  3. Change From Baseline in in Daytime Total Sleep Time [ Time Frame: Baseline, 14 days follow-up ]
  4. Change From Baseline in Number of Daytime Naps [ Time Frame: Baseline, 14 days follow-up] ]
  5. Change in Cognitive Function (as Measured by the Mini-Mental State Examination) [ Time Frame: Baseline, 14 days follow-up] ]
  6. Change in Activities of Daily Living (The Index of ADL - Katz) [ Time Frame: Baseline, 14 days follow-up] ]
  7. Change of Baseline in Behavioral Variables (BAHAVE-AD Scale) [ Time Frame: Baseline, 14 days follow-up] ]
  8. Change From Baseline in Cognitive Function (Digit Symbol Substitution Test) [ Time Frame: Baseline, 14 days follow-up] ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Fifty-five years of age or older; Diagnosis of probable Alzheimer's disease by National Institute of Neurological and Communicative Disorders and Stroke/the Alzheimer's Disease and Related Disorders Association criteria; Hachinski Ischemia Scale score less than 5 Mini-Mental State Examination score of O to 26 Actigraph evidence of a mean time immobile of less than 7 hours per night based on at least 7 nights of complete actigraph data collected over a single week; For-week history of sleep disorder behaviors, occurring at least once weekly, as reported by the caregiver using the Neuropsychiatric Inventory (NPI) Nighttime Behavior scale; Sleep disturbance observed was not present before the diagnosis of AD; Other co-morbidities, especially delirium, depression, chronic pain and medication use may be present, but do not cooperate in the primary symptoms; Computed tomography or magnetic resonance imaging since the onset of memory problems showing no more than 1 lacunar infarct in a nonstrategic area and no clinical events suggestive of stroke or other intracranial disease or normal; Stable medications for 4 weeks prior to the screening visit; Having a mobile upper extremity to which to attach an actigraph; Residing with a responsible spouse, family member, or professional caregiver who is present during the night and would agree to assume the role of the principal caregiver for the 3-week protocol; Ability to ingest oral medication and participate in all scheduled evaluations

Exclusion Criteria:

Sleep disturbance associated with an acute illness, delirium or psychiatric disease; Clinically significant movement disorder, such as akinesia, that would affect actigraphic differentiation of sleep and wakefulness Severe agitation; Unstable medical condition; Discontinuation of psychotropic or sleep medications within 2 weeks of the screening visit; Patient unwilling to maintain caffeine abstinence after 2:00 PM for the duration of the protocol; Patient unwilling to comply with the maximum limit of 2 alcoholic drinks per day, and only 1 alcoholic drink after 6:00 PM for the duration of the protocol; Prior use of mirtazapine for the treatment of sleep disturbances; Caregiver deemed too unreliable to supervise the wearing of the actigraph, to administer trazodone the proper time, to maintain tbe sleep diary, or to bring the patient to the scheduled visits;

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01867775


Locations
Brazil
Brasilia University Recruiting
Brasilia, Distrito Federal, Brazil, 70840
Contact: Francisca M Scoralick       franciscascoralick@gmail.com   
Sub-Investigator: Francisca M Scoralick         
Sponsors and Collaborators
Brasilia University Hospital
Investigators
Principal Investigator: Francisca M Scoralick, MD University of Brasilia
More Information

Responsible Party: Einstein Francisco de Camargos, Medical Doctor, Brasilia University Hospital
ClinicalTrials.gov Identifier: NCT01867775     History of Changes
Other Study ID Numbers: 052/2012
First Posted: June 4, 2013    Key Record Dates
Last Update Posted: June 4, 2013
Last Verified: May 2013

Keywords provided by Einstein Francisco de Camargos, Brasilia University Hospital:
Alzheimer's disease
Sleep disorders
Mirtazapine
Treatment
Intervention
insomnia

Additional relevant MeSH terms:
Disease
Alzheimer Disease
Sleep Wake Disorders
Parasomnias
Pathologic Processes
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Neurologic Manifestations
Signs and Symptoms
Mirtazapine
Mianserin
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Serotonin Antagonists